Gaming giant Aristocrat has commenced legal action against rival Ainsworth, claiming a “controversial” game designer used confidential information to develop a competing slot machine.
The judge overseeing a case brought by Meat & Livestock Australia over a bovine gene patent has given parties until July 5 to oppose changes to the patent, held by Cargill and Branhaven, after an earlier ruling invalidated the patent.
The ACCC will face a test of its ability to win misuse of market power cases when a long-awaited judgment is handed down this week in the regulator’s appeal of a ruling dismissing its case alleging Pfizer misused its market power in the months leading up to the expiration of the patent for its blockbuster cholesterol drug Lipitor.
For the third time this year, IP Australia has upheld a challenge to a coffee capsule patent, finding that the patent, owned by a unit of German food giant Kruger, was not inventive.
Two generic drug makers are fighting for access to confidential documents related to amendments by Neurim Pharmaceutical of patents covering its sleep drug Circadin, telling the Federal Court on Thursday privilege had been waived after a phone conversation between the company’s founder and her lawyers from DLA Piper.
Drug giant F. Hoffman-La Roche asked the Federal Court Tuesday for an order barring the release of a generic version of its blockbuster cancer drug MabThera by a unit of Swiss rival Novartis, which it claims could lead to “tens of millions of dollars” in losses.
SNF has filed an appeal with the Federal Court after the Australian Patent Office shot down its challenge to a mining patent application by rival BASF.
Take-Two Interactive has won a temporary injunction blocking a gamer from making unauthorised changes to its popular Grand Theft Auto video game.
Telecom giant Optus has come up short in a Federal Court challenge to trademark registration for health services company Optum, with a judge saying the two company’s marks — despite the difference of just one letter — were distinct enough.
A full bench of the Federal Court has dismissed an appeal by drug giant GlaxoSmithKline in a patent infringement case it brought over planned generic versions of its sustained-release Panadol.